Compare Cognizant Technology Solutions Corp (CTSH) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Inovio Pharmaceuticals Inc — how do they compare? Cognizant Technology Solutions Corp trades at $58.99 (market cap $26.40B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Cognizant Technology Solutions Corp is far larger — about 336.1× Inovio Pharmaceuticals Inc's market cap, and Cognizant Technology Solutions Corp pays a 2.25% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTSH | INO | |
|---|---|---|
Market Cap | $26.40B | $78.55M |
Sector | Technology | Health |
52-Week High | $86.70 | $2.87 |
52-Week Low | $38.73 | $0.66 |
Enterprise Value | $27.44B | $49.56M |
Dividend Yield | 2.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cognizant (CTSH) trades at $58.19, down 0.21% today, with a bullish technical signal and strong cash flow. Recent Q2 2026 earnings missed estimates at $1.37 EPS, but revenue beat. The company maintains a solid net income margin of 10.26% and trades at a P/E of 12.58, below industry averages. Analyst consensus is mixed with a $59.92 price target, and the stock shows resilience amid AI-driven strategic shifts.
Outlook remains cautiously optimistic with upside potential from AI initiatives and financial services growth, though risks include client spending caution and competitive pressures. The stock's current valuation offers a margin of safety, but investors should monitor execution on AI integration and macroeconomic headwinds affecting IT spending.
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
